ALLIANCES (Pfizer) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended										1 Months Ended	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013 Eliquis [Member]	Dec. 31, 2012 Eliquis [Member]	Dec. 31, 2013 Pfizer [Member]	Dec. 31, 2012 Pfizer [Member]	Dec. 31, 2013 Pfizer [Member] Eliquis [Member]	Dec. 31, 2012 Pfizer [Member] Eliquis [Member]	Dec. 31, 2011 Pfizer [Member] Eliquis [Member]	Jan. 31, 2014 Pfizer [Member] Eliquis [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2013 Pfizer [Member] Eliquis [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 Pfizer [Member] Eliquis [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2011 Pfizer [Member] Eliquis [Member] Upfront, milestone and other licensing payments [Member]
Alliances Statement [Line Items]
Minimum percentage of reimbursement for development costs from alliance partner																50.00%
Maximum percentage of reimbursement for development costs from alliance partner																60.00%
Total upfront, milestone and other licensing payments received to date																				$ 784
Upfront, milestone and other licensing payments received																			20	205	20	65
Potential additional development and regulatory milestone receipts																				100
Net product sales									12,304	13,654	17,622			144	2
Alliance and other revenues									4,081	3,967	3,622			2
Total Revenues	4,441	4,065	4,048	3,831	4,191	3,736	4,443	5,251	16,385	17,621	21,244	146	2	146	2
Cost of products sold - Profit sharing																69	1
Cost reimbursements to/(from) alliance partner																4	(11)	(75)
Other (income)/expense - Amortization of deferred income																				(41)	(37)	(33)
Deferred income	$ 1,525				$ 4,849				$ 1,525	$ 4,849										$ 581	$ 397